Darunavir concentrations in CSF of HIV‐infected individuals when boosted with cobicistat versus ritonavir

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jac/dkx165PMID 28575323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

  2016cited by this paper
• Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity

  2016cited by this paper
• Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.

  2015cited by this paper
• Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.

  2015cited by this paper
• Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

  2015cited by this paper
• Pharmacokinetics of darunavir in fixed‐dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers

  2014cited by this paper
• Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations

  2014cited by this paper
• The brain entry of HIV-1 protease inhibitors is facilitated when used in combination.

  2013cited by this paper
• Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration.

  2013cited by this paper
• Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

  2012cited by this paper
• Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.

  2010cited by this paper
• Regulation of ABC membrane transporters in glial cells: Relevance to the pharmacotherapy of brain HIV‐1 infection

  2008cited by this paper
• Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.

  2005cited by this paper
• Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients

  2004cited by this paper

• Pharmacokinetic approaches to standardize antiviral exposure in cerebrospinal fluid

  2025cites this paper
• Darunavir Nanoformulation Suppresses HIV Pathogenesis in Macrophages and Improves Drug Delivery to the Brain in Mice

  2024cites this paper
• In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cells

  2024cites this paper
• Intranasal delivery of darunavir improves brain drug concentrations in mice for effective HIV treatment

  2022cites this paper
• CNS Considerations in ART Simplification Strategies

  2021cites this paper
• SARS-CoV-2, an Underestimated Pathogen of the Nervous System

  2020cites this paper
• Pharmacologic approaches to HIV-associated neurocognitive disorders.

  2020cites this paper
• Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

  2018cites this paper
• Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

  2018cites this paper
• Darunavir for the treatment of HIV infection

  2018influential citation
• Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1

  2018cites this paper
• Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

  2018cites this paper
• Preclinical assessment of nirmatrelvir penetration into cerebrospinal �uid and central nervous system cells and tissues

  year unknowncites this paper